|
|
|
|
Dr Reddy's resolves Clarinex patent litigation with Schering and Sepracor
Dr Reddy's will also market a generic version of the Clarinex 5mg tablet six months after the launch of the first generic version of that product.The agreements resolve all pending patent infringement actions filed by Schering and...
|
|
|
Dr. Reddy's Laboratories settles Clarinex (Desloratadine) ANDA patent litigation with Schering Corporation an
Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr.Reddy's to manufacture and market generic versions of the CLARINEX-D-12 Hour and CLARINEX-D -24 Hour products, with...
|
|
|
Chronic urticaria: the autoimmune paradigm
Philpott K et al.- Recent evidence indicates that at least a subset of patients in whom no extrinsic or internal cause can be identified are in fact autoimmune in origin. This is based mainly on the detection of pathogenic...
|
|
|
Dr. Reddy?s Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Scherin
Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr.Reddys to manufacture and market generic versions of the CLARINEX-D -12 Hour and CLARINEX-D -24 Hour products, with...
|
|
|
Dr. Reddy's Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Schering
- Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddy's to manufacture and market generic versions of the CLARINEX-D-12 Hour and CLARINEX-D -24 Hour products,...
|
|
|
Dr. ReddyEURs Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Sch
- Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddys to manufacture and market generic versions of the CLARINEX-D-12 Hour and CLARINEX-D -24 Hour products,...
|
|
|
Dr. Reddy's Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Schering
Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr.Reddy's to manufacture and market generic versions of the CLARINEX-D-12 Hour and CLARINEX-D -24 Hour products, with...
|
|
|
Dr. ReddyEURs Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Sch
Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr.Reddys to manufacture and market generic versions of the CLARINEX-D-12 Hour and CLARINEX-D -24 Hour products, with six...
|
|
|
Dr. Reddys Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Schering
HYDERABAD, India--(BUSINESS WIRE)--Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddys to manufacture and market generic versions of the CLARINEX-D-12 Hour...
|
|
|
Dr. Reddy's Laboratories Announce Settlement of Clarinex(R) (Desloratadine) ANDA Patent
Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr.Reddy's to manufacture and market generic versions of the CLARINEX-D(R)-12 Hour and CLARINEX-D(R) -24 Hour products,...
|
|
|
Dr. Reddys Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With S
HYDERABAD, India -- (Business Wire) Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddys to manufacture and market generic versions of the CLARINEX-D-12 Hour...
|
|
|
Dr. Reddys Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Schering
HYDERABAD, India--(BUSINESS WIRE)--Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddys to manufacture and market generic versions of the CLARINEX-D-12 Hour...
|
|
|
Dr. Reddy's Laboratories Announce Settlement of Clarinex (Desloratadine) ANDA Patent litigation With Schering
HYDERABAD, India (Business Wire) -- Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddy's to manufacture and market generic versions of the CLARINEX-D-12 Hour...
|
|
|
Dr. Reddy's Laboratories Announce Settlement of Clarinex(R) (Desloratadine) ANDA Patent litigation With Scheri
HYDERABAD, India--(BUSINESS WIRE)-- Dr.Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddy's to manufacture and market generic versions of the CLARINEX-D(R)-12...
|
|
|
Cumberland wins approval for updated labeling of Acetadote injection
The FDA decision is based on a recent Canadian study evaluating 4,709 adults and 1,905 children who were treated with intravenous (IV) acetylcysteine for acetaminophen overdose.Data from the multi-center study comprises the largest known...
|
|
|
Quadrivalent HPV vaccine hypersensitivity uncommon
MedWire News: True hypersensitivity to the quadrivalent human papillomavirus (HPV) vaccine is uncommon, a large study of Australian schoolgirls suggests.The researchers found that even girls with suspected hypersensitivity were often able...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
NASHVILLE, Tenn., Dec.18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote(R) (acetylcysteine) Injection, the company's intravenous...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote
Revised label includes additional safety data from more than 6,500 patients NASHVILLE, Tenn., December 18, 2008 /PRNewswire/ -- Cumberland Pharmaceuticals announced today that the U.S.Food and Drug Administration (FDA) has approved...
|
|
|
Cumberland wins approval for updated labeling of Acetadote injection
US-based Cumberland Pharmaceuticals has announced that the FDA has approved updated labeling for Acetadote injection, the company's intravenous treatment for acetaminophen overdose.The revised package insert provides new information from...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
NASHVILLE, Tenn., Dec.18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote(R) (acetylcysteine) Injection, the company's intravenous...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
NASHVILLE, Tenn., Dec.18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote(R) (acetylcysteine) Injection, the company's intravenous...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
The FDA decision is based on a recent Canadian study evaluating 4,709 adults and 1,905 children who were treated with IV acetylcysteine for acetaminophen overdose.Data from the multi-center study comprises the largest known database...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
Revised label includes additional safety data from more than 6,500 patients NASHVILLE, Tenn., Dec.18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved updated...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
Revised label includes additional safety data from more than 6,500 patients NASHVILLE, Tenn., Dec.18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved updated...
|
|
|
Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
NASHVILLE, Tenn.(Photo: http://www.newscom.com/cgi-bin/prnh/20081218/CLTH084 ) The FDA decision is based on a recent Canadian study evaluating 4,709 adults and 1,905 children who were treated with IV acetylcysteine for acetaminophen...
|
